Logo
x

Search

Subscribe Now

Celltrion

Celltrion’s SteQeyma (Biosimilar, Stelara) Receives the EC’s Approval to Treat Various Chronic Inflammatory Diseases

Celltrion’s SteQeyma (Biosimilar, Stelara) Receives the EC’s Approval to Treat Various Chronic Inflammatory Diseases

  • August 26, 2024
Celltrion’s Steqeyma (Biosimilar, Stelara) Receives the Health Canada’s Approval to Treat Various Chronic Inflammatory Conditions

Celltrion’s Steqeyma (Biosimilar, Stelara) Receives the Health Canada’s Approval to Treat Various Chronic Inflammatory Conditions

  • August 2, 2024
The EC Grants Approval to Celltrion’s Omlyclo (Biosimilar, Xolair)

The EC Grants Approval to Celltrion’s Omlyclo (Biosimilar, Xolair)

  • May 27, 2024
Celltrion’s CT-P39 (biosimilar, omalizumab) Receives the CHMP’s Recommendation for Marketing Authorization to Treat Multiple Indications

Celltrion’s CT-P39 (biosimilar, omalizumab) Receives the CHMP’s Recommendation for Marketing Authorization to Treat Multiple Indic...

  • March 25, 2024
Celltrion Submits BLA to the US FDA for CT-P39 (Biosimilar, Xolair)

Celltrion Submits BLA to the US FDA for CT-P39 (Biosimilar, Xolair)

  • March 11, 2024
Insights+ Key Biosimilars Events of February 2024

Insights+ Key Biosimilars Events of February 2024

  • March 4, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.